Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pear Therapeutics Adds Two PDTs To Treat Depression

Executive Summary

Pear Therapeutics acquired a digital therapeutic for depression from Waypoint Health and licensed an Internet-based cognitive behavior therapy program for residual symptoms of depression from a psychologist in Sweden.

You may also be interested in...



Pear Adds Spanish Version Of Its Addiction Therapy PDTs

Availability of Spanish-language prescription digital therapeutics for the treatment of substance use disorder and opioid use disorder will address important health equity and health care disparities, according to Pear.

Pear CEO Sees Fulfilment And Reimbursement Challenges Ahead

Medtech Insight spoke to Pear Therapeutics CEO Corey McMann about the emerging digital therapeutics market and his company’s future now that it has the first PDT covered by Medicaid.

‘Training People To Be Healthier’: Digital Therapeutics Programmed For Growth

Experts foresee the digital therapeutics market growing to $6bn-$9bn by 2025, driven in part by tech-empowered consumers and patients looking for solutions to better manage their own health and conditions. For medtechs, collaborations with software-driven start-ups will be key to harnessing personalized data and differentiating themselves in the marketplace.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT144853

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel